Date: 2016-04-26
Type of information: Services contract
Compound: ABX464
Company: Abivax (France) PCAS (France)
Therapeutic area: Infectious diseases
Type agreement: production manufacturing services contract
Action mechanism: splice modulating agent. ABX464 is a first-in-class, small molecule inhibiting HIV replication through the inhibition of the Rev protein activity and modulation of RNA splicing. In collaboration with the team of Professor Jamal Tazi at the CNRS in Montpellier, France, ABIVAX designed ABX464 to lead to a clinically relevant improvement in HIV therapy. Preclinical data in humanized mice demonstrated that ABX464 monotherapy had an antiviral effect that was sustained following treatment interruption (Campos et al, Retrovirology 2015 12:30). A prior food-effect study demonstrated a three-fold increase in parent drug exposure when administered with food, without a significant impact on active glucuronide
metabolite.
Disease: HIV infection
Details: * On April 25, 2016, Abivax and PCAS announced that they have signed with a contract for the production and supply of ABX464, ABIVAX’s drug candidate for the treatment of HIV. Under the contract signed by the two companies, PCAS will synthesize and manufacture ABX464, and will ensure its availability for the completion of the Phase II and Phase III
trials to be carried out by Abivax. These trials are scheduled for 2016 and following years. Abivax has transferred the process for producing ABX464 to PCAS, which began manufacturing ABX464 on behalf of Abivax in March of this year while initiating a process optimization program. This collaboration is expected to be extended further for commercial supply once the clinical program has been completed and the required authorizations obtained.
Financial terms:
Latest news:
